ESMO 2016

Area: Oncology

Location: Copenhagen, Denmark

Date: October 7 to October 11

Description:

European Society for Medical Oncology Conference.


Search in Scientific Content:
Date
Filters:
Vision of
5:31

Vision of the ESMO

Presenter: Fortunato Ciardiello
Oncology
13890_PR <
5:20

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

Presenter: Lidija Kandolf-Sekulovic
Oncology
ESMO 2016:
5:42

ESMO 2016: Scientific Programme Highlights

Presenter: Andres Cervantes
Oncology
Anti-cance
5:30

Anti-cancer medicines

Presenter: Joseph Tabernero
Oncology

Full-dose neoadjuvant chemotherapy: Interi

Presenter: Alessandro Gronchi
Oncology

EORTC 18071

Presenter: Alexander M.M. Eggermont
Oncology
First-line...
9:49

First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

Presenter: Gabriel N. Hortobagyi
Oncology

Primary analyss from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC.

Presenter: Fabrice Barlesi
Oncology
ASCEND-5 s
9:40

ASCEND-5 study

Presenter: Giorgio Scagliotti
Oncology

AFFINITY phase 3 trial. Chemotherapy of Prostate Cancer

Presenter: Karim Fizazi
Oncology

Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)

Presenter: Alain Ravaud
Oncology

Results from ALLIANCE A031203 trial

Presenter: Toni Choueiri
Oncology
Eribulin i
4:48

Eribulin in Soft Tissue Sarcomas (Leiomyosarcoma)

Presenter: Jean-Yves Blay
Oncology
ESMO 2016:
6:12

ESMO 2016: Congress Highlights

Presenter: Andres Cervantes
Oncology

13890_PR < 5000 patients denied access to new, life-saving drugs every year in Europe

Presenter: Lidija Kandolf-Sekulovic
Oncology
MONALEESA-
8:02

MONALEESA-2 study and Novelties in breast cancer therapy

Presenter: Gabriel N. Hortobagyi
Oncology

Full-dose neoadjuvant chemotherapy

Presenter: Alessandro Gronchi
Oncology

EORTC 18071

Presenter: Alexander M.M. Eggermont
Oncology
Vision of
3:13

Vision of the ESMO

Presenter: Fortunato Ciardiello
Oncology
New result
4:30

New results in immun check point inhibition Lung Cancer

Presenter: Federico Cappuzzo
Oncology

The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: An international multicentre hospital-based retrospective cohort study

Presenter: Matteo Lambertini
Oncology

Highlights of Late Breaking Trials

Presenter: Stefan Zimmermann
Oncology

Checkpoint inhibitors for the treatment of orphan malignancies

Presenter: Paolo A. Ascierto
Oncology
New therap
4:02

New therapeutical option: A mechanism of action study. An oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma.

Presenter: Ignacio Duran
Oncology
Highlights
6:08

Highlights of Late Breaking Trials

Presenter: Evandro de Azambuja
Oncology

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States

ELCC 2016

2016-04-13 - 2016-04-16
Geneva, Switzerland

ESMO ECCO 2015

2015-09-25 - 2015-09-29
Vienna, Austria

ASCO 2015

2015-05-29 - 2015-06-02
Chicago, United States

ELCC 2015

2015-04-15 - 2015-04-18
Geneva, Switzerland

Bratislava 2014

2014-10-09 - 2014-10-10
Bratislava, Slovakia

ESMO 2014

2014-09-26 - 2014-09-30
Madrid, Spain